Kazia Therapeutics doses first patient in PNOC035 study
Kazia Therapeutics says its first patient was dosed in PNOC035, a clinical study evaluating paxalisib for recurrent pediatric AT/RT brain cancer.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Kazia Therapeutics doses first patient in PNOC035 paxalisib AT/RT study
Kazia Therapeutics said the first patient was dosed in its PNOC035 multicenter study evaluating paxalisib plus gemcitabine for recurrent or progressive pediatric AT/RT.